Berkshire Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
Other funds holding IONS
VPM
VCM
Berkshire Asset Management's IONS Position: Q1 2026 in Review
Berkshire Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 0.19% in Q1 2026, buying an estimated $552 and bringing the position to 3,637 shares worth $273K. The position accounts for 0.01% of the portfolio, ranked #227.
Berkshire Asset Management first reported a position in IONS in Q1 2019 and has held it in 17 quarters since. The position peaked at $698K in Q4 2020. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Berkshire Asset Management held 3,637 shares of Ionis Pharmaceuticals worth $273K as of Q1 2026.
- Berkshire Asset Management bought 7 Ionis Pharmaceuticals shares in Q1 2026, an estimated $552.
- Ionis Pharmaceuticals made up 0.01% of Berkshire Asset Management's portfolio in Q1 2026, its #227 holding.
- Berkshire Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and has held it in 17 quarters since.
- Berkshire Asset Management's Ionis Pharmaceuticals position peaked at $698K in Q4 2020.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.